During the past decade, Ruttenberg Treatment Center conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Ruttenberg Treatment Center" are "Primary Myelofibrosis" (2 trials), "Castration-Resistant Prostatic Cancer" (1 trials), "Castration-Resistant Prostatic Neoplasms" (1 trials), "ET-MF" (1 trials) and "MPN-associated Myelofibrosis" (1 trials). Many other conditions were trialed in "Ruttenberg Treatment Center" in a lesser frequency.

Most popular intervention types in "Ruttenberg Treatment Center" are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Abiraterone Acetate" (1 trials), "Apalutamide 240 mg" (1 trials), "Canakinumab" (1 trials) and "Cetrelimab 480 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Ruttenberg Treatment Center" are 2 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Ruttenberg Treatment Center". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Ruttenberg Treatment Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Ruttenberg Treatment Center, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".